OBJECTIVE: To explore the pharmacokinetics and pharmacodynamics of dopamine and norepinephrine. DESIGN: Prospective, controlled, trial. SETTING: Neurosciences critical care unit. PATIENTS: Eight patients with a head injury, requiring dopamine or norepinephrine infusions to support cerebral perfusion pressure (CPP). INTERVENTION: Patients received in randomised order, either dopamine or norepinephrine to achieve and maintain a CPP of 70 mmHg, and then, following a 30-min period of stable haemodynamics, a CPP of 90 mmHg. Data were then acquired using the second agent. Haemodynamic measurements were made during each period and a blood sample was obtained at the end of each study period for analysis of plasma catecholamine concentrations MEASUREMENTS AND RESULTS:Plasma levels of norepinephrine and dopamine were significantly related to infusion rates but did not have a simple linear relationship to haemodynamic parameters. However, there was a significant quadratic relationship between the infusion rate of dopamine and cardiac index (r2=0.431), and systemic vascular resistance index (r2=0.605), with a breakpoint (at which cardiac index reduced and SVRI increased) at a dopamine plasma level of approximately 50 nM/l (corresponding to an infusion rate of approximately 15 microg.kg(-1).min(-1)). CONCLUSIONS:Norepinephrine and dopamine have predictable pharmacokinetics; however, those of dopamine do not fit a simple first-order kinetic model. The pharmacodynamic effects of dopamine and norepinephrine show much inter-individual variability and unpredictability. Plasma levels of dopamine appear to relate to variations in adrenergic receptor effects with break points that reflect expectations from infusion-rate related pharmacodynamics.
RCT Entities:
OBJECTIVE: To explore the pharmacokinetics and pharmacodynamics of dopamine and norepinephrine. DESIGN: Prospective, controlled, trial. SETTING: Neurosciences critical care unit. PATIENTS: Eight patients with a head injury, requiring dopamine or norepinephrine infusions to support cerebral perfusion pressure (CPP). INTERVENTION: Patients received in randomised order, either dopamine or norepinephrine to achieve and maintain a CPP of 70 mmHg, and then, following a 30-min period of stable haemodynamics, a CPP of 90 mmHg. Data were then acquired using the second agent. Haemodynamic measurements were made during each period and a blood sample was obtained at the end of each study period for analysis of plasma catecholamine concentrations MEASUREMENTS AND RESULTS: Plasma levels of norepinephrine and dopamine were significantly related to infusion rates but did not have a simple linear relationship to haemodynamic parameters. However, there was a significant quadratic relationship between the infusion rate of dopamine and cardiac index (r2=0.431), and systemic vascular resistance index (r2=0.605), with a breakpoint (at which cardiac index reduced and SVRI increased) at a dopamine plasma level of approximately 50 nM/l (corresponding to an infusion rate of approximately 15 microg.kg(-1).min(-1)). CONCLUSIONS:Norepinephrine and dopamine have predictable pharmacokinetics; however, those of dopamine do not fit a simple first-order kinetic model. The pharmacodynamic effects of dopamine and norepinephrine show much inter-individual variability and unpredictability. Plasma levels of dopamine appear to relate to variations in adrenergic receptor effects with break points that reflect expectations from infusion-rate related pharmacodynamics.
Authors: N P Day; N H Phu; N T Mai; D B Bethell; T T Chau; P P Loc; L V Chuong; D X Sinh; T Solomon; G Haywood; T T Hien; N J White Journal: Crit Care Med Date: 2000-05 Impact factor: 7.598
Authors: A Payton; J Holmes; J H Barrett; T Hever; H Fitzpatrick; A L Trumper; R Harrington; P McGuffin; M O'Donovan; M Owen; W Ollier; J Worthington; A Thapar Journal: Am J Med Genet Date: 2001-07-08
Authors: Mellissa M C DeMille; Judith R Kidd; Valeria Ruggeri; Meg A Palmatier; David Goldman; Adekunle Odunsi; Friday Okonofua; Elena Grigorenko; Leslie O Schulz; Batsheva Bonne-Tamir; Ru-Band Lu; Josef Parnas; Andrew J Pakstis; Kenneth K Kidd Journal: Hum Genet Date: 2002-10-01 Impact factor: 4.132
Authors: C P Zabetian; G M Anderson; S G Buxbaum; R C Elston; H Ichinose; T Nagatsu; K S Kim; C H Kim; R T Malison; J Gelernter; J F Cubells Journal: Am J Hum Genet Date: 2001-01-19 Impact factor: 11.025
Authors: Peter Andrews; Elie Azoulay; Massimo Antonelli; Laurent Brochard; Christian Brun-Buisson; Geoffrey Dobb; Jean-Yves Fagon; Herwig Gerlach; Johan Groeneveld; Jordi Mancebo; Philipp Metnitz; Stefano Nava; Jerome Pugin; Michael Pinsky; Peter Radermacher; Christian Richard; Robert Tasker; Benoit Vallet Journal: Intensive Care Med Date: 2005-01-28 Impact factor: 17.440
Authors: Christoph Tschuor; Lars M Asmis; Philipp M Lenzlinger; Martina Tanner; Luc Härter; Marius Keel; Reto Stocker; John F Stover Journal: Crit Care Date: 2008-06-18 Impact factor: 9.097